Anthony J. Recupero Sells 3,941 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBNGet Free Report) insider Anthony J. Recupero sold 3,941 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $15.10, for a total transaction of $59,509.10. Following the completion of the sale, the insider now owns 247,592 shares in the company, valued at approximately $3,738,639.20. The sale was disclosed in a filing with the SEC, which is accessible through this link.

SI-BONE Stock Performance

NASDAQ:SIBN opened at $14.92 on Friday. The business has a 50 day simple moving average of $15.44 and a 200 day simple moving average of $17.90. The company has a debt-to-equity ratio of 0.22, a quick ratio of 8.75 and a current ratio of 9.76. SI-BONE, Inc. has a 12-month low of $13.96 and a 12-month high of $29.51.

SI-BONE (NASDAQ:SIBNGet Free Report) last announced its quarterly earnings results on Monday, February 26th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.02. The company had revenue of $38.86 million during the quarter, compared to the consensus estimate of $38.60 million. SI-BONE had a negative net margin of 29.93% and a negative return on equity of 25.14%. On average, equities analysts anticipate that SI-BONE, Inc. will post -0.95 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Brown Advisory Inc. raised its holdings in shares of SI-BONE by 5.4% during the fourth quarter. Brown Advisory Inc. now owns 4,207,703 shares of the company’s stock valued at $88,320,000 after buying an additional 214,089 shares during the last quarter. First Light Asset Management LLC increased its position in SI-BONE by 0.9% in the 4th quarter. First Light Asset Management LLC now owns 2,547,392 shares of the company’s stock valued at $53,470,000 after acquiring an additional 23,299 shares during the period. Vanguard Group Inc. increased its position in SI-BONE by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 2,463,501 shares of the company’s stock valued at $40,328,000 after acquiring an additional 43,670 shares during the period. Champlain Investment Partners LLC raised its stake in SI-BONE by 104.8% during the 1st quarter. Champlain Investment Partners LLC now owns 2,453,147 shares of the company’s stock valued at $40,158,000 after acquiring an additional 1,255,610 shares in the last quarter. Finally, Granahan Investment Management LLC boosted its position in SI-BONE by 13.2% during the 4th quarter. Granahan Investment Management LLC now owns 1,286,450 shares of the company’s stock worth $27,003,000 after acquiring an additional 150,217 shares during the period. 98.11% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on SIBN. Needham & Company LLC restated a “buy” rating and set a $27.00 price objective on shares of SI-BONE in a research note on Tuesday, May 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price target on shares of SI-BONE in a research report on Tuesday, February 27th. JMP Securities restated a “market outperform” rating and set a $32.00 price objective on shares of SI-BONE in a research note on Tuesday, May 7th. Piper Sandler assumed coverage on shares of SI-BONE in a research note on Thursday, March 28th. They set an “overweight” rating and a $25.00 target price for the company. Finally, Morgan Stanley reduced their price target on shares of SI-BONE from $26.00 to $25.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 7th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $27.29.

Get Our Latest Research Report on SI-BONE

About SI-BONE

(Get Free Report)

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

Read More

Insider Buying and Selling by Quarter for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.